View Post

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

In In The News by Barbara Jacoby

Source: Eli Lilly and Company From: PR Newswire – Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types – CureVac to receive an upfront payment of $50 million and an equity investment of €45 million Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on …